Nyxoah SA Business Summary

Nyxoah SA (NYXH) is a medical technology firm specializing in the development and commercialization of the Genio system, an FDA-approved (August 2025) and CE-marked bilateral hypoglossal neurostimulation therapy for Obstructive Sleep Apnea (OSA). The company generates revenue primarily through the sale of its leadless, battery-free implantable neurostimulators and associated disposable components, with business segments divided between its established European/International operations and its rapidly scaling U.S. commercial market. Following its full U.S. launch in late 2025, Nyxoah reported preliminary FY2025 net revenue of approximately €10.0 million, a 122% year-over-year increase fueled by the activation of over 50 U.S. accounts and the training of nearly 150 surgeons. Its primary direct competitors include Inspire Medical Systems, LivaNova, and NeuroPace; Nyxoah positions itself as the leading challenger to Inspire’s market dominance by offering a less invasive, sensing-lead-free alternative that simplifies surgical implantation and enhances patient comfort. The company was founded by Chairman Robert Taub, a prominent entrepreneur who previously founded Omrix Biopharmaceuticals (acquired by Johnson & Johnson). Leadership is directed by CEO Olivier Taelman, a neuromodulation veteran with over 20 years of experience at industry leaders such as Medtronic, Stryker, and Nevro, where he successfully managed clinical-to-commercial transitions. The executive team is further strengthened by CTO Bruno Onkelinx, who brings 15 years of expertise in active implantable devices from Cochlear, and CFO John Landry, a medtech finance specialist with over two decades of experience in public and private sectors. Nyxoah is supported by a high-pedigree board and strategic investors, including hearing-implant leader Cochlear, sleep-respiratory giant ResMed, and Gilde Healthcare, alongside independent directors with deep backgrounds at BASF and Medtronic.